Revvity, Inc. (RVTY)

NYSE: RVTY · IEX Real-Time Price · USD
116.11
+0.44 (0.38%)
Jun 2, 2023, 12:20 PM EDT - Market open
0.38%
Market Cap 14.57B
Revenue (ttm) 3.36B
Net Income (ttm) 961.69M
Shares Out 125.44M
EPS (ttm) 7.60
PE Ratio 15.22
Forward PE n/a
Dividend $0.28 (0.24%)
Ex-Dividend Date Jul 20, 2023
Volume 219,614
Open 116.11
Previous Close 115.67
Day's Range 114.08 - 116.12
52-Week Range 113.17 - 170.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Jul 31, 2023

About RVTY

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical techno... [Read more]

Sector Healthcare
Founded 1937
Employees 11,000
Stock Exchange NYSE
Ticker Symbol RVTY
Full Company Profile

Financial Performance

In 2023, Revvity's revenue was $3.31 billion, a decrease of -13.48% compared to the previous year's $3.83 billion. Earnings were $569.18 million, a decrease of -39.65%.

Financial Statements

News

Revvity's EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) syst...

1 day ago - Business Wire

Revvity to Present at Goldman Sachs Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 44th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. PT at the Waldorf Astoria ...

1 week ago - Business Wire

PerkinElmer Completes Transformation to Become Revvity

On Tuesday, May 16, the name PerkinElmer and its PKI symbol disappeared from the stock market. In its place is a piece of the old company, branded as Revvity Inc. ( RVTY , Financial).

2 weeks ago - GuruFocus
}

Revvity Announces Financial Results for the First Quarter of 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compar...

3 weeks ago - Business Wire

PerkinElmer Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on Aug...

1 month ago - Business Wire

PerkinElmer to Hold Earnings Call on Thursday, May 11, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc. (NYSE: PKI), today announced that it will release its first quarter 2023 financial results prior to market open on Thursday, May 11, 2023. The Company...

1 month ago - Business Wire

Dirk Bontridder Appointed as CEO of New PerkinElmer Business Acquired by New Mountain Capital

NEW YORK--(BUSINESS WIRE)--The new PerkinElmer business acquired by New Mountain Capital announced today the appointment of Dirk Bontridder as Chief Executive Officer effective March 13, 2023. The new...

2 months ago - Business Wire

PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc. (NYSE: PKI), today announced that it has successfully completed the previously announced divestiture of its Applied, Food and Enterprise Services busi...

2 months ago - Business Wire
}

PerkinElmer to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the virtual KeyBanc Capi...

3 months ago - Business Wire

PerkinElmer Launches EnVison Nexus Multimode Plate Reader to Drive Improved Research and Discovery Workflows

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer launches EnVision® Nexus™ system, its fastest, most sensitive multimode reader yet, for HTS to accelerate drug discovery efforts.

3 months ago - Business Wire

PerkinElmer to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Cowen 43rd Annual He...

3 months ago - Business Wire

PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year end...

3 months ago - Business Wire

Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA

Mr. Rongen appointed as CEO and member of the Board bringing 30 years of executive leadership experience and expertise across a number of therapeutic areas Bolstered expertise on Board of Directors wi...

Other symbols: MTNB
4 months ago - Accesswire
}

Prahlad Singh Appointed to Board of Directors of Amphenol Corporation

WALLINGFORD, Conn.--(BUSINESS WIRE)--Amphenol Corporation (NYSE: APH) today announced that Prahlad Singh, PhD has been appointed to Amphenol's board of directors. With his appointment, the size of t...

Other symbols: APH
5 months ago - Business Wire

PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it will release its fourth quarter and full year 2...

5 months ago - Business Wire

PerkinElmer to Present at J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan...

5 months ago - Business Wire

PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detect...

6 months ago - Business Wire

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the U.S. Food and Drug Administration (FDA) has aut...

7 months ago - Business Wire

PerkinElmer to Present at 2022 Stifel Healthcare Conference

WALTHAM, Mass.

7 months ago - Business Wire

EPIC SCIENCES EXPANDS EXECUTIVE TEAM AND WELCOMES NEW CHIEF FINANCIAL OFFICER IN PREPARATION FOR RAPID GROWTH

Bill Kullback Brings Proven Track Record of Scaling Companies for Successful Outcomes SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnos...

7 months ago - PRNewsWire

PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-k...

8 months ago - Business Wire